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ABSTRACT
Introduction: Topical ophthalmic formulations
of corticosteroids are commonly used to treat a
variety of ocular diseases and conditions that
have an inflammatory component. The purpose
of this study was to evaluate the effect of the
mucus-penetrating particle (MPP) technology
on the pharmacokinetic profile of loteprednol
etabonate in the ocular tissues of rabbits.
Methods: Forty-eight New Zealand White
rabbits were randomly assigned to two groups
(n = 3 rabbits or 6 eyes per time point) and
treated with either the novel loteprednol
etabonate MPP suspension formulation, 0.4%
(LE-MPP 0.4%), or the commercial Lotemax-
brand loteprednol etabonate ophthalmic
suspension, 0.5% (Lotemax 0.5%) (Bausch &
Lomb Incorporated, Inc., Rochester, NY, USA).
Samples of aqueous humor, various ocular
tissues, and plasma were collected from
animals over a 12-h period after a single dose
of the test articles. Loteprednol etabonate
concentrations were assayed using liquid
chromatography–tandem mass spectrometry
(LC/MS/MS).
Results: Loteprednol etabonate was rapidly
absorbed into ocular tissues following
administration of either formulation. A higher
ocular exposure was achieved using LE-MPP
0.4%, with peak concentrations of
approximately threefold higher in ocular
tissues and the aqueous humor than Lotemax
0.5%.
Conclusions: Administration of LE-MPP 0.4%
improved loteprednol etabonate
pharmacokinetic profile in ocular tissues of
rabbits. The results of this study support the
premise that the MPP technology can be used to
enhance ocular exposure for topically applied
therapeutic agents. Further studies to assess the
clinical efficacy and safety of the LE-MPP
formulation are warranted.
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INTRODUCTION
Ocular inflammation, if left untreated, can lead
to temporary or permanent vision loss.
Corticosteroids have been a mainstay in
treating a variety of ocular diseases and
conditions that have an inflammatory
component due to their ability to elicit broad
anti-inflammatory effects. Loteprednol
etabonate, a corticosteroid that was developed
for ophthalmic use, was designed using the soft
drug concept in an effort to retain the
therapeutic corticosteroid activity while
minimizing adverse side effects [1, 2].
Loteprednol etabonate has been available
for ophthalmic use in a variety of formulations
for the past 15 years. Clinical studies
evaluating the safety and efficacy of
loteprednol etabonate have been performed
for a number of ophthalmic conditions,
including dry eye [3], seasonal allergic
conjunctivitis [4], anterior uveitis [5], giant
papillary conjunctivitis [6, 7], and treatment of
pain and inflammation following cataract
surgery [8–10]. Additionally, studies with
various steroids assessing the risk of
intraocular pressure (IOP) elevation, a
common concern associated with ocular
steroids, indicate that there may be reduced
risk for loteprednol etabonate, as compared to
other corticosteroids [11–13].
Topical application of therapeutic agents
provides direct access to the target tissue;
however, the ocular surface provides a set of
unique challenges for topical penetration.
Mechanisms to eliminate foreign material
from the ocular surface include blinking, tear
flow, and drainage through the nasolacrimal
duct. Moreover, cornea and conjunctiva are
naturally covered with a 3- to 40-lm layer of
mucus [14–16]. The outer layer is comprised of
secreted and other mucins (cleared rapidly by
mucin turnover and blinking), whose primary
role is to trap and eliminate allergens,
pathogens and debris (including therapeutic
particles) from the eye [17]. The inner layer
(up to 500-nm thick) is formed by epithelium-
tethered mucins (glycocalyx), which protect the
corneal tissue from abrasive stress and are
cleared less rapidly [17]. Drug carriers that can
penetrate the rapidly cleared outer mucous
layer and reach the slow-clearing glycocalyx
are likely to reside at the ocular surface longer
and facilitate drug release directly to the
underlying tissue. However, conventional
attempts to improve retention of agents on
ocular surface often focus on designing
ophthalmic formulations with higher
viscosity, such as ointments or gels, which
may have tolerability issues [18].
In an effort to circumvent the barrier
presented by the mucous layers, novel
formulations have been developed using a
proprietary method to create mucus-
penetrating nanoparticles [19]. This drug
delivery platform allows for diffusion through
the mucus and facilitates an even distribution
of the nanoparticles across the ocular surface.
The overall goal of the loteprednol etabonate
mucus-penetrating particles suspension
formulation, 0.4% (LE-MPP 0.4%) is to
improve drug penetration into tissues
underlying the mucous barrier.
A previous report based on 14C-labeled
loteprednol etabonate indicated that topical
administration of Lotemax 0.5% suspension
(Bausch & Lomb Incorporated, Inc., Rochester,
NY, USA) results in a relatively high distribution
into the cornea, with reduced penetration into
the aqueous humor and iris/ciliary body [20]. In
this study, we investigate the effect of using a
novel MPP formulation on the pharmacokinetic
profile of loteprednol etabonate in the ocular
tissues of rabbits.
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MATERIALS AND METHODS
A total of 48 male New Zealand White rabbits
ranging from 4 to 5 months of age (weights
ranged from 2.41 to 3.33 kg) were used in this
study. Rabbits were housed individually under
standard conditions, provided water and dry
rabbit feed pellets ad libitum, and were allowed
8 days to acclimatize to the facility conditions
prior to study initiation. The experiment was
conducted according to the standards of the
Association of Research and Vision in
Ophthalmology (ARVO) statement for the use
of Animals in Ophthalmic and Vision Research.
The study design was reviewed and approved by
the facility Institutional Review Board. All
institutional and national guidelines for the
care and use of laboratory animals were followed.
A novel ophthalmic formulation of LE-MPP
was prepared using a proprietary technology as
described elsewhere [21]. Briefly, to generate LE-
MPP, a milling procedure was employed in
which an aqueous dispersion containing
coarse drug particles and an MPP-enabling
surface-altering agent was milled with grinding
medium until particle size was reduced to
approximately 200 nm with a polydispersity
index less than 0.15 as measured by dynamic
light scattering. The LE-MPP 0.4% formulation
is a suspension of loteprednol etabonate
nanoparticles formulated with excipients
approved by the US Food and Drug
Administration (FDA) for ophthalmic use. The
formulation is essentially isotonic with a near-
neutral pH and, similarly to Lotemax
suspension, contains 0.01% of benzalkonium
chloride as the preservative. The LE-MPP
formulation is shelf-stable (chemically and
physically) at controlled room temperature
(15–25 C). The chemical purity of loteprednol
etabonate in the final LE-MPP 0.4% formulation
used in this study was greater than 97%.
Lotemax-brand loteprednol etabonate
ophthalmic suspension, 0.5% (Lotemax 0.5%)
was obtained from commercially available
supplies (Bausch & Lomb Incorporated, Inc.,
Rochester, NY, USA) and used as a comparator
in this study.
Rabbits were randomly assigned to two
treatment groups. After gentle shaking, a single
50 microliter (lL) drop of either Lotemax 0.5% or
LE-MPP 0.4% was administered to both eyes of
each rabbit using a positive displacement pipette
(Gilson, Inc., Middleton, WI, USA). The rabbits
were gently restrained for approximately 2 min
after the dosing to prevent the animals from
shaking their heads or pawing at the eyes. At each
of the following time points, 0.083, 0.25, 0.5, 1.0,
3.0, 6.0, and 12.0 h post-dosing, three rabbits
from each treatment group were euthanized by
intravenous barbiturate overdose and plasma
samples were obtained. Both eyes from each
rabbit were harvested, and samples were
collected from the aqueous humor, conjunctiva,
cornea, iris/ciliary body, and central retina.
Ocular irritation assessments were
conducted according to the method reported
by Draize et al. [22], for all animals prior to
dosing (pre-dose) and prior to the necropsy.
All samples were assayed using liquid
chromatography–tandem mass spectrometry
(LC/MS/MS). The analysis for each matrix was
performed separately, and tissue-specific
standard curves were generated separately for
both formulations. For animals treated with
Lotemax 0.5%, the analytical method had a
lower limit of quantification (LLOQ) of 0.02 ng/
mL for plasma, 0.01 ng/mL for aqueous humor,
0.1 ng/g for cornea and iris/ciliary body, 2.0 ng/
g for conjunctiva, and 0.4 ng/g for retina. For
animals treated with LE-MPP 0.4%, the LLOQ
was 0.02 ng/mL for plasma, 0.01 ng/mL for
aqueous humor, 0.1 ng/g for cornea, 0.2 ng/g
for conjunctiva and iris/ciliary body, and
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0.4 ng/g for retina. Plasma and aqueous humor
samples were diluted with control plasma or
aqueous humor, respectively, and analyzed
directly. Ocular tissue samples were weighed,
homogenized, and diluted with methanol prior
to analysis.
Statistical Analysis
The mean and the standard error of the mean
(SEM) of loteprednol etabonate concentrations
were calculated for each time point.
WinNonlin software (Pharsight Corporation,
Mountain View, CA, USA), version 6.2.1, was
used to calculate the pharmacokinetic
parameters for each matrix: area under the
concentration–time curve from the first time
point to 12 h (AUC0–last); area under the
concentration–time curve from the first time
point extrapolated to infinity (AUC0–inf);
maximum concentration observed (Cmax),
elimination half-life (T1/2); and time to reach
maximum concentration (Tmax). The log-linear
trapezoidal rule was used to calculate AUCs. A
‘‘best fit’’ model was used to calculate the T1/2.
Prior to the calculations, any mean with a
%CV[100 was checked for outliers at the
p\0.01 level using the Grubbs’ Test. If a value
was confirmed as an outlier, it was not included
in the pharmacokinetic calculation. Unpaired
t test was used to identify statistical significance
between experimental groups receiving LE-MPP
0.4% to the comparator groups receiving
Lotemax 0.5% using Prism version 6 software
(GraphPad Software, San Diego, CA, USA).
P values less than 0.05 were considered
significant.
RESULTS
Samples from all 48 rabbits (96 eyes) were
included in the analysis for this study. Rabbits
in all groups had normal appearing ocular
tissues pre-dose and prior to necropsy. No
abnormal scores were observed per the Draize
method of scoring [22].
Concentrations of loteprednol etabonate in
the aqueous humor are shown in Fig. 1. For
Fig. 1 Pharmacokinetic proﬁle of loteprednol etabonate in
rabbit aqueous humor. The mean loteprednol etabonate
concentrations ± SEM (ng/mL) for rabbits treated with
Lotemax 0.5% (circles), or LE-MPP 0.4% (squares) is
depicted for the aqueous humor samples. The value shown
for each time point is the mean ± SEM for six samples
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both formulations, Tmax was observed at 0.5 h
(30 min) after administration, with LE-MPP
0.4% showing an approximately threefold and
twofold higher Cmax and AUC0–12 h,
respectively, than that of Lotemax 0.5%.
Loteprednol etabonate concentrations in the
cornea and conjunctiva following a single dose
of either Lotemax 0.5% or LE-MPP 0.4% are
shown in Fig. 2. The drug absorbed rapidly into
the tissues from both formulations, with the
highest levels observed at the earliest time point
of 0.083 h (5 min), then declining towards the
LLOQ after the first 3 h. Nevertheless, the peak
levels in the cornea and conjunctiva were 3.6-
and 2.6-fold higher, respectively, for LE-MPP
0.4% than those for Lotemax 0.5%. The
AUC0–12 h, was 1.5-fold higher in the cornea
for LE-MPP 0.4% than that of Lotemax 0.5%.
Concentrations of loteprednol etabonate in
the iris/ciliary body and retina are shown in
Fig. 2 Pharmacokinetic proﬁle of loteprednol etabonate in
rabbit cornea and conjunctiva. The mean loteprednol
etabonate concentrations ± SEM (ng/g) for rabbits treated
with Lotemax 0.5% (circles), or LE-MPP 0.4% (squares) is
depicted for cornea (a) or conjunctiva (b). The value shown
for each time point is the mean ± SEM for six samples
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Fig. 3. Tmax in the iris/ciliary body was observed
at 0.25 h (15 min) for LE-MPP 0.4%, and at 0.5 h
(30 min) for Lotemax 0.5% (Fig. 3a). Tmax in the
retina (Fig. 3b) occurred at 0.5 h (30 min) for
both formulations. Cmax and AUC0–12 h was
approximately threefold and twofold higher,
respectively, in animals treated with LE-MPP
0.4% than in those treated with Lotemax 0.5%
in the iris/ciliary body and retina.
A summary of pharmacokinetic parameters
in ocular tissues and plasma is presented in
Table 1. A comparison of the values by tissue
indicates a generally higher Cmax and AUC for
the LE-MPP 0.4% formulation, with the
exception of conjunctiva, where the AUC
values were similar between the two
formulations. Plasma levels were also
enhanced for the LE-MPP 0.4% formulation,
Fig. 3 Pharmacokinetic proﬁle of loteprednol etabonate in
rabbit iris/ciliary body and retina. The mean loteprednol
etabonate concentrations ± SEM (ng/g) for rabbits treated
with Lotemax 0.5% (circles), or LE-MPP 0.4% (squares) is
depicted for the iris/ciliary body (a) or retina (b). The value
shown for each time point is the mean ± SEM for six
samples
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although overall systemic exposure is low for
both formulations.
DISCUSSION
In this study, we observed that the preparation
of a loteprednol etabonate ophthalmic
suspension using the MPP technology resulted
in an improved pharmacokinetic profile in the
ocular tissues of New Zealand White rabbits
when compared to Lotemax 0.5% suspension.
Administration of a single drop of the LE-MPP
0.4% formulation resulted in higher levels of
loteprednol etabonate in the conjunctiva at the
earliest time point of 0.083 h (5 min). It should
be noted that, based on the rapid dissolution of
LE-MPP nanoparticles observed in vitro under
sink conditions, the drug detected in the
conjunctiva even at this earliest time point is
likely molecularly absorbed in the tissue rather
than imbedded in the tissue as intact
nanoparticles. In addition, an approximately
Table 1 Pharmacokinetic parameters (mean ± SEM) for loteprednol etabonate following a single ocular dose of Lotemax








(ng h/mL or ng h/g)
AUC0–inf
(ng h/mL or ng h/g)
Aqueous humor
Lotemax 0.5% 2.31 0.50 6 ± 1 14 ± 2 14
LE-MPP 0.4% 1.57 0.50 20 ± 3 31 ± 1 31
Cornea
Lotemax 0.5% 3.75 0.083 621 ± 56 1130 ± 173 1,270
LE-MPP 0.4% 1.89 0.083 2260 ± 470 1670 ± 130 1,690
Conjunctiva
Lotemax 0.5% 4.26 0.083 1130 ± 177 1610 ± 238 1,900
LE-MPP 0.4% 1.92 0.083 2930 ± 250 1610 ± 140 1,630
Iris/Ciliary body
Lotemax 0.5% 3.04 0.50 49 ± 6 91 ± 5 93
LE-MPP 0.4% 1.49 0.25 137 ± 14 206 ± 10 208
Retina (center punch)
Lotemax 0.5% 9.18 0.50 2.1 ± 0.2 6.9 ± 1.3 10
LE-MPP 0.4% 1.55 0.50 6.8 ± 1.2 14.7 ± 1.8 15
Plasma
Lotemax 0.5% 1.88 0.25 0.33 ± 0.06 0.76 ± 0.06 0.79
LE-MPP 0.4% 1.71 0.25 1.19 ± 0.26 2.12 ± 0.27 2.20
AUC0–last: area under the concentration–time curve from the ﬁrst time point to 12 h; AUC0–inf: area under the
concentration–time curve from the ﬁrst time point to inﬁnity (extrapolated); Cmax maximum concentration observed; T1/2
elimination half-life; Tmax time to reach Cmax. Data presented as mean ± SEM, as appropriate. Cmax is reported as either ng/
mL or ng/g for ﬂuid and tissue samples, respectively. Parameters pertaining to AUC are reported as either ng h/mL or ng h/
g for ﬂuid and tissue samples, respectively
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threefold higher Cmax was observed in the
aqueous humor, cornea, iris/ciliary body, and
retina, indicating that LE-MPP 0.4% enabled a
higher level of absorption in ocular tissues. The
threefold higher Cmax resulting from
administration of LE-MPP 0.4% is particularly
noteworthy as the formulation contains 20% less
active drug than Lotemax 0.5%. Although rabbits
are the species of choice for topical
pharmacokinetic studies, it remains to be seen if
theseenhancements translate intohumans.These
data support the premise that the MPP technology
can enhance exposure of topically applied drugs.
The results of this study generally agree with
the previously published distribution profile of
loteprednol etabonate in ocular tissues following
topical administration, in that the highest levels
of drug exposure are found on the ocular surface
(corneal and conjunctival tissues) shortly after
administration, while comparatively reduced
levels of loteprednol etabonate penetrate past
the ocular surface (aqueous humor, iris/ciliary
body, and retina) [20]. However, the LC/MS/MS
analytical method employed in the present study
(compared to the use of radio-labeled drug
material in the previous study), allows for a
direct quantitation of loteprednol etabonate in
ocular tissues.
Topical delivery of therapeutic agents offers
the distinct benefit of application of a high
concentration of the active agent at the desired
site of action. In the case of ophthalmic
formulations, relatively high doses of drug are
easily delivered to the ocular surface. However,
retention time of an ophthalmic formulation
on the ocular surface limits the effectiveness of
a product after instillation. Nanoparticles have
the potential to improve ocular exposure from
topical administration; however, this effort had
been undermined by adhesion of virtually all
synthetic nanoparticles to the ocular mucous
layer, which protects the eye by effectively
trapping and rapidly clearing foreign particles
from the ocular surface [17, 23]. Ocular
residence time of such nanoparticles is,
therefore, limited by the turnover rate of the
peripheral ocular mucus, typically on the order
of seconds to minutes. To enhance topical
ocular delivery, drug carriers must avoid
entrapment by, and readily penetrate through,
the mucous layer of the eye. The increase in
exposure of ocular tissues to loteprednol
etabonate with LE-MPP 0.4% as compared to
Lotemax 0.5% in this study indicates that MPP
formulation of loteprednol etabonate may have
resulted in a longer retention time on the ocular
surface.
CONCLUSION
The LE-MPP 0.4% formulation used in this study
produced increased levelsof loteprednoletabonate
in ocular tissues and fluids when compared to
Lotemax 0.5% suspension. The enhanced
pharmacokinetic profile of loteprednol etabonate
seen in this study supports further investigation
into whether the LE-MPP formulation may allow
for a reduction in the dosing frequency and/or
dosing concentration in clinical applications.
Further studies to assess the efficacy and safety of
the LE-MPP formulation for clinical applications
are warranted.
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